Abstract
Background High number of SARS-CoV-2 infected patients has overburdened healthcare delivery system, particularly in low-income countries. In the recent past many studies from the developed countries have been published on the prevalence of SARS CoV-2 antibodies and the risk factors of COVID-19 in healthcare-workers but little is known from developing countries.
Methods This cross-sectional study was conducted on prevalence of SARS-CoV-2 antibody and risk factors for seropositivity in HCWs in tertiary-care hospitals of Peshawar city, Khyber Pakhtunkhwa province Pakistan.
Results The overall seroprevalence of SARS CoV-2 antibodies was 30·7% (CI, 27·8–33·6) in 1011 HCWs. Laboratory technicians had the highest seropositivity (50·0%, CI, 31·8–68·1).
Risk analysis revealed that wearing face-mask and observing social-distancing within a family could reduce the risk (OR:0·67. p<0·05) and (OR:0·73. p<0·05) while the odds of seropositivity were higher among those attending funeral and visiting local-markets (OR:1·83. p<0·05) and (OR:1·66. p<0·01). In Univariable analysis, being a nursing staff and a paramedical staff led to higher risk of seropositivity (OR:1.58. p< 0·05), (OR:1·79. p< 0·05). Fever (OR:2·36, CI, 1·52– 3·68) and loss of smell (OR:2·95, CI: 1·46–5·98) were significantly associated with increased risk of seropositivity (p<0.01). Among the seropositive HCWs, 165 (53·2%) had no symptoms at all while 145 (46·8%) had one or more symptoms.
Conclusion The high prevalence of SARS-CoV-2 antibodies in HCWs warrants for better training and use of protective measure to reduce their risk. Early detection of asymptomatic HCWs may be of special importance because they are likely to be potential threat to others during the active phase of viremia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding Agency: Prime Foundation Pakistan Grand no: 2020-6-CG-0001
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval obtained from Ethical Review board of Prime Foundation, Pakistan
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data related to our research study is avilable and can be provided upon request